Study: Bone drug cuts risk of breast cancer relapse

06/1/2008 | USA Today · Wall Street Journal, The

Zometa, Novartis AG's bone-building drug, lowered the chances of breast cancer recurrence by 35% in premenopausal women with early-stage, hormone-sensitive breast cancer when combined with hormone therapy, a study of more than 1,800 patients found. The findings also showed that 9% of those who did not take Zometa in addition to hormone treatments either died or experienced a recurrence, compared with 6% of those who received the drug.

View Full Article in:

USA Today · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT